[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-adjuvant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-adjuvant":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100538765","phase-2-the-efficacy-of-pipac-and-minimally-invasive-radical-resection-in-high-risk-gastric-cancer-patients-100538765",false,"NCT06295094","The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.","The Efficacy of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined With CURativE Intent Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. A Multicentre, Randomised, Open-label Phase-II Study","EPICURE","Inclusion criteria\n\n* Gastric or Gastroesophageal junction Siewert type III adenocarcinomas\n* Clinical T3-4a-stages\n\n  1. Any differentiation grade\n  2. Any histological subtype\n* Clinical T2-stage\n\n  a. If poorly differentiated or of the poorly cohesive histological subtype, with or without the presence of signet-ring cells\n* Any clinical T-stage with positivity for malignant cells on abdominal lavage cytology, which is converted to cytology negative in response to neoadjuvant chemotherapy.\n* Any clinical nodal-stage\n* clinical M0-stage (positive abdominal wash cytology, which is converted to cytology negative in response to neoadjuvant therapy, is permitted)\n* Performance status Eastern Cooperative Oncology Group (ECOG) 0-1\n* Age 18 - 80 years\n* Undergoing robotic or laparoscopic D2 gastrectomy\n* Able and willing to provide written informed consent and to comply with the clinical study protocol\n* Fertile women must have a negative pregnancy test at the time of inclusion and must use adequate contraception.\n\nExclusion criteria\n\n* Previous allergic reaction to cisplatin, doxorubicin or other platinum-containing compounds.\n* Renal impairment, defined as glomerular filtration rate (GFR) \\\u003C 40 ml\u002Fmin (Cockcroft-Gault Equation).\n* Myocardial insufficiency, defined as New York Heart Association (NYHA) class 3-4.\n* An impaired liver function, defined as bilirubin ≥ 1.5 x upper normal limit (UNL).\n* An inadequate haematological function, defined as absolute neutrophil count (ANC) \\\u003C1.5 x 109\u002Fl and platelets \\\u003C100 x 109\u002Fl.\n* Any other condition or therapy which, in the investigator's opinion, may pose a risk to the patient or interfere with the study objectives.","ALL","18 Years","80 Years",{"count":21,"type":22},264,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this randomized clinical trial is to investigate whether pressurized intraperitoneal chemotherapy (PIPAC), delivered immediately after minimally invasive D2 gastrectomy and repeated 6-8 weeks later, improves 12-month peritoneal disease-free survival in patients with high-risk gastric adenocarcinoma when compared to standard treatment.",[28,29,30,31],"Gastric Cancer","Chemotherapy, Adjuvant","Peritoneal Metastases","Minimally Invasive Surgical Procedures",[33,34,35],"PIPAC","Gastric cancer","Minimally invasive gastrectomy","NOT_YET_RECRUITING","2024-03-05",{"date":39,"type":40},"2024-03-06","ACTUAL",{"date":42,"type":22},"2024-09",{"date":44,"type":22},"2028-01",{"name":46,"class":47},"Odense University Hospital","OTHER",5,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100312776","phase-2-surgery-with-or-without-chemotherapy-for-stage-i-nsclc-with-micropapillary-component--20-100312776","NCT03351842","Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%","A PHASE II STUDY Of ADJUVANT CHEMOTHERAPY After SURGERY For STAGE I Lung ADENOCARCINOMA PATIENTS With MICROPAPILLARY COMPONENT More Than Or EQUAL To 20%","Inclusion Criteria:\n\n* Completely resected Stage I NSCLC as defined by the International Staging System\n* Pathologically diagnosed Stage I micropapillary predominant lung adenocarcinoma\n* Patients must be randomized within 4 weeks from the date of surgery\n* No prior chemotherapy or radiation for non-small cell lung cancer\n* Performance status of 0 or 1\n* Women must be non-pregnant and non-lactating; patients of childbearing potential must agree to use an effective form of contraception while on study\n* Patients must have no history of previous or concomitant malignancy, other than curatively treated carcinoma in situ of the cervix, or basal cell or squamous cell carcinoma of the skin, or surgically treated in situ carcinoma of the breast, or other cancer for which the patient has been disease free for five years\n* Granulocytes \\>= 1,800\u002Ful\n* Platelets \\>= 100,000\u002Ful\n* Bilirubin \\\u003C 1.5 mg\u002Fdl\n* SGOT(serum glutamic-oxaloacetic transaminase) (AST) \\\u003C 2.0 x ULN(upper limit of normal value)\n\nExclusion Criteria:\n\n* Do not meet the inclusion criteria\n* There is evidence of distant metastases\n* Suffered from other malignancies in five years\n* Within the past January subjects received other drug trials\n* Having serious allergies or idiosyncratic persons, such as you can not use folic acid, dexamethasone, vitamin B12 patients\n* Severe lung or heart disease, a history\n* Refuses or is unable to sign informed consent to participate in trials\n* The abuse of drugs or alcohol addicts.\n* Patients with difficult to control bacterial, viral, fungal infections\n* Having a personality or mental disorders, without civil capacity or restricted civil capacity.\n* Being pregnant or lactating women.","19 Years","70 Years",{"count":59,"type":22},460,[25],"Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.",[29,63,64,65],"Lung Adenocarcinoma, Stage I","Treatment","Histological Type of Neoplasm",[67,68,69],"Adjuvant chemotherapy","Micropapillary Component","Early stage lung cancer","RECRUITING","2017-12-17",{"date":73,"type":40},"2017-12-19",{"date":75,"type":40},"2017-09-01",{"date":77,"type":22},"2024-09-01",{"name":79,"class":47},"Shanghai Pulmonary Hospital, Shanghai, China",1]